Psychiatric and Cognitive Manifestations of Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

Psychiatric and Cognitive Manifestations of Parkinson's Disease: A Prospective Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00360633
• Other study ID #: 12-03082
• Status: Completed
• Start date: June 2006
• Est. completion date: March 28, 2019

Study information

• Verified date: May 2019
• Source: New York University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, most patients also experience psychiatric and cognitive symptoms, sometimes from the disease itself, and sometimes as a side-effect of PD medications. The goals of this study are to evaluate the causes, effects, and clinical correlates of psychiatric and cognitive symptoms in PD.

Description:

Parkinson's Disease (PD) is defined by the presence of motor symptoms, but in recent years there has been increasing recognition of non-motor manifestations, including anxiety, depression, and cognitive symptoms. In addition, PD medications have been shown to cause impulse control disorders, cognitive changes, and non-motor withdrawal symptoms (dopamine agonist withdrawal syndrome) when they are discontinued. The goals of this study are to test the hypothesis that the presence of psychiatric and cognitive symptoms are associated with greater self-perceived disability (out of proportion to objective deficits), increased utilization of healthcare resources, and decreased quality of life. In addition, we will examine the clinical correlates of these psychiatric symptoms. To test these hypotheses, we will screen PD patients for anxiety, depression, impulse control disorders, and dopamine agonist withdrawal syndrome, and compare cases and controls with regard to demographic characteristics, motor features of PD, disability, healthcare utilization, and quality of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: March 28, 2019
• Est. primary completion date: March 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson's Disease (or healthy control subject)

• Age >=21 and <=99

• Capacity to provide informed consent

• Ability to complete the questionnaires

Exclusion Criteria:

• Clinical diagnosis of dementia

• Terminal illness (life expectancy < 12 months)

• Presence of a neurodegenerative disorder other than Parkinson's Disease

Related Conditions & MeSH terms

• Neurobehavioral Manifestations
• Parkinson Disease
• Parkinson's Disease

Locations

Country	Name	City	State
United States	NYU School of Medicine	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Non-motor symptom progression		Chronic
Secondary	Motor symptom progression		Chronic

External Links

•   NYU Parkinson's Disease and Movement Disorders Center